Curative Therapies for Non-Small Cell Lung Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 1860

Special Issue Editor


E-Mail Website
Guest Editor
Department of Oncology, Marshall University Chief of Radiation Oncology, Edwards Comprehensive Cancer Center, Huntington, WV, USA
Interests: lung cancer; radiotherapy; surgery; immunotherapy

Special Issue Information

Dear Colleagues,

On behalf of Cancers, I would like to announce a call for articles for a Special Issue entitled “Curative Therapies for Non-Small Cell Lung Cancer”. In this rapidly changing world of lung cancer therapeutics, we are seeing patients live much longer lives. At Cancers, we recognize that during the last decade, we have observed a remarkable increase in patient survival due to the better selection and refinement of techniques for surgery and radiotherapy, as well as the growing armamentarium of systemic therapies including tyrosine kinase inhibitors for actionable mutations, immunotherapy with or without chemotherapy, and anti-angiogenic therapy combined with immunotherapy.

We will be considering all options for “curative” therapy, including neo-adjuvant/adjuvant therapy for resectable disease, treatments for locally advanced disease, local therapies for oligometastatic disease (de novo, recurrent or persistent), as well as the long-term curative potential of systemic therapies.

Dr. John Michael Varlotto
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • radiotherapy
  • surgery
  • early-stage NSCLC
  • oligometastases
  • immunotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 947 KiB  
Article
Outcomes of Multimodal Treatment in Elderly Patients with Localized Non-Small Lung Cancer from a Radiation Oncology Point of View: Special Focus on Low-Dose Cisplatin
by Niklas Josua Alt, Julian Muster, David Alexander Ziegler, Stephanie Bendrich, Sandra Donath, Andrea Hille, Mahalia Zoe Anczykowski, Carla Marie Zwerenz, Friederike Braulke, Alexander von Hammerstein-Equord, Tobias Raphael Overbeck, Hannes Treiber, Manuel Guhlich, Rami El Shafie, Stefan Rieken, Martin Leu and Leif Hendrik Dröge
Cancers 2024, 16(2), 327; https://doi.org/10.3390/cancers16020327 - 11 Jan 2024
Viewed by 1387
Abstract
Identification of the optimal treatment strategy is challenging in elderly with localized non-small cell lung cancer (NSCLC). Concurrent chemotherapy with low-dose cisplatin represents an option for elderly. Outcomes (1) in elderly (≥70 years, n = 158) vs. younger patients (n = 188) [...] Read more.
Identification of the optimal treatment strategy is challenging in elderly with localized non-small cell lung cancer (NSCLC). Concurrent chemotherapy with low-dose cisplatin represents an option for elderly. Outcomes (1) in elderly (≥70 years, n = 158) vs. younger patients (n = 188) and (2), independently of age, in definitive radiochemotherapy, with low-dose cisplatin (n = 125) vs. cisplatin/vinorelbine (n = 76) were studied. Elderly included more males, had a lower Karnofsky index, more comorbidities, and lower stages. Low-dose cisplatin patients (vs. cisplatin/vinorelbine) had higher age, more comorbidities, and lower stages. We observed reduced dermatitis and dysphagia and increased anemia and thrombocytopenia in elderly vs. younger patients, without increased ≥grade 3 toxicities. Low-dose cisplatin was less toxic than cisplatin/vinorelbine. Survival outcomes were lower in elderly vs. younger and comparable between low-dose cisplatin and cisplatin/vinorelbine. In elderly, gender, Karnofsky index, stage, and multimodal treatment (including additional surgery/systemic therapy) were identified as prognostic factors. In conclusion, we found evidence for an acceptable toxicity profile and the need for improvement of outcomes in elderly with localized NSCLC. Multimodal strategies (including additional surgery/systemic treatment) showed favorable outcomes and should be reasonably considered in elderly who are deemed fit enough. Low-dose cisplatin should be discussed on an individual basis due to favorable toxicity and outcomes. Full article
(This article belongs to the Special Issue Curative Therapies for Non-Small Cell Lung Cancer)
Show Figures

Figure 1

Back to TopTop